Completed PHASE3 INTERVENTIONAL 2-arm NCT01437371

Is There a Benefit to Optimize Heart Failure (HF) Treatment in Aged Over 80 Year's Old Patients? (HF 80)

Is There a Benefit to Optimize HF (Heart Failure) Treatment in Aged Over 80 Year's Old Patients?

Sponsor: LivaNova

Interventions - Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.

Updated 5 times since 2017 Last updated: Sep 30, 2014 Started: Aug 31, 2011 Primary completion: Jun 30, 2014 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01437371, this PHASE3 trial focuses on Heart Failure and remains completed. Sponsored by LivaNova, it has been updated 5 times since 2011, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

LivaNova
Servier
University Hospital, Clermont-Ferrand

Data source: University Hospital, Clermont-Ferrand

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Clermont-Ferrand, France